Unlock instant, AI-driven research and patent intelligence for your innovation.

Fusion protein and nucleic acid containing peptide carrier and epidermal growth factor and its uses

A technology of epidermal growth factor and fusion protein, applied in the field of modified epidermal growth factor, can solve the problems of difficult to penetrate mucous membrane, difficult to penetrate skin, restricting deep tissue and systemic drug use, etc.

Inactive Publication Date: 2009-08-19
INST OF PHARMACOLOGY & TOXICOLOGY ACAD OF MILITARY MEDICAL SCI P L A
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

EGF is not easy to penetrate the skin and mucous membrane, so it is only suitable for wound and mucous membrane surface, which limits the possibility of its deep tissue and systemic administration

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fusion protein and nucleic acid containing peptide carrier and epidermal growth factor and its uses
  • Fusion protein and nucleic acid containing peptide carrier and epidermal growth factor and its uses
  • Fusion protein and nucleic acid containing peptide carrier and epidermal growth factor and its uses

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0146] Construction and Identification of Expression Vector pPTD-hEGF

[0147] The synthetic EGF gene (SEQ ID NO: 1) was connected to the pBS-T carrier (purchased from Beijing Tianwei Times Company), and the target gene was excised from the T carrier with Kpn I+EcoR I, recovered and purified; I+EcoR I double-enzyme cut expression vector pPTD (the nucleotide sequence (SEQ ID NO: 3) of the synthetic PTD was connected to the carrier pRSET (purchased from Invitrogen, San Diego, CA) and constructed), and the purified vector was reclaimed Fragment; Take the appropriate ratio of the recovered target gene fragment and the target carrier fragment, and at T 4 Under the action of DNA ligase, connect overnight at 16°C, take appropriate ligation solution to transform competent cell TOP10 (purchased from Beijing Tianwei Times Company), and select a few from the clone plaques grown on the screening medium for culture and identification.

[0148] The plasmids of the recombinant colonies were...

Embodiment 2

[0150] Expression of PTD-hEGF fusion protein

[0151] Extract the correct expression vector constructed above to transform Escherichia coli BL21(DE3), pick multiple clones for induced expression, figure 2 is the expression status of one of the typical clones, and it can be seen from the figure that the plasmid has been effectively expressed. According to biological software analysis, the expression amount accounts for 40% of the total bacterial protein.

Embodiment 3

[0153] Determination of expression form of recombinant protein

[0154] After the cells induced to express were collected by centrifugation, they were washed with PBS buffer, and then the washed cells were dissolved in an appropriate lysate, the cells were disrupted by ultrasonic waves, and the supernatant and precipitate were separated by centrifugation. The results of SDS-PAGE analysis showed that , the target protein content in the supernatant is very small, and most of them exist as insoluble inclusion bodies. Take equal amounts of lysate precipitates and dissolve them in 2, 4, 6, and 8M urea respectively. Electrophoresis analysis shows that the solubility of the inclusion body is the largest in 8M urea ( image 3 ).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the modification of human epidermal growth factor, and discloses fusion proteins containing peptide-carrier sequence (preferably protein transduction domain (PTD)) and epidermal growth factor (EGF), nucleic acids encoding them, compositions containing them and their use. The compounds and compositions provided by the invention can be used as the active components or additives for medicaments, health products and cosmetics.

Description

technical field [0001] The present invention relates to the modification of epidermal growth factor. Specifically, the present invention relates to modified epidermal growth factors with strong penetrating ability, nucleic acids encoding them, compositions containing them and uses thereof. Background technique [0002] Epidermal growth factor was discovered, extracted and isolated in the submandibular gland of mice by Cohen (Life Sci.1965, 4(17): 1625-33) in 1962. It is a single-chain polypeptide consisting of 53 amino acid residues. There is no Alanine, Phenylalanine and Lysine. It has three disulfide bonds that are necessary for its biological activity. EGF causes a series of biochemical changes in cells by transducing signals, activates genes related to cell division, and makes quiescent cells enter the cell division cycle, thereby causing cell proliferation. A very small amount can strongly promote cell division and growth. EGF is not easy to penetrate the skin and m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K19/00C12N15/11C12N15/29C12N15/63A61K38/18A61K8/64A61P1/04A61P17/00A61P11/00C12N15/62
Inventor 智庆文李前王玉霞李仕贵孙曼霁
Owner INST OF PHARMACOLOGY & TOXICOLOGY ACAD OF MILITARY MEDICAL SCI P L A